CSF3 and cancer: Because systemic administration of 5–10 μg G-CSF/kg/day is commonly used for pediatric malignancies [64, 66–68], the results shown here indicate that notably low doses of G-CSF (1–5 μg/defect/2 weeks) with controlled release can promote osteogenesis.